J. May

发表

Small-molecule agonists for the glucagon-like peptide 1 receptor

Jeppe Sturis, Jarek Kostrowicki, Carsten Behrens, 2007, Proceedings of the National Academy of Sciences.

N‐0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease

J. Belluzzi, E. Domino, D. McAfee, 2004, Movement disorders : official journal of the Movement Disorder Society.

Y1 and Y2 receptor selective neuropeptide Y analogues: evidence for a Y1 receptor subclass.

J. Rivier, M. Pelleymounter, M. Cullen, 1995, Journal of medicinal chemistry.

Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor.

J. Holst, J. D. de Jong, Michael D. Johnson, 2007, Bioorganic & medicinal chemistry letters.

Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.

A. Kuki, Michael D. Johnson, D. Murphy, 2002, Journal of medicinal chemistry.

Human glucagon receptor antagonists based on alkylidene hydrazides.

A. Kuki, D. Murphy, A. Polinsky, 2002, Bioorganic & medicinal chemistry letters.

Identification of alkylidene hydrazides as glucagon receptor antagonists.

A. Kuki, D. Murphy, A. Polinsky, 2001, Journal of medicinal chemistry.

Biological Characterization of a Novel, Orally Active Small Molecule Gonadotropin-Releasing Hormone (GnRH) Antagonist Using Castrated and Intact Rats

Mark B. Anderson, G. Paderes, D. Luthin, 2003, Journal of Pharmacology and Experimental Therapeutics.

Regulation of β-adrenoceptor density and function in rat vas deferens

P. Abel, K. Minneman, J. May, 1986 .

Thyroid status and adrenergic receptor subtypes in the rat: comparison of receptor density and responsiveness.

P. Abel, K. Minneman, A. Fox, 1985, The Journal of pharmacology and experimental therapeutics.

In vitro and in vivo pharmacological characterization of N6-cyclopentyl-9-methyladenine (N-0840): a selective, orally active A1 adenosine receptor antagonist.

J. Miller, J. May, R. J. Barrett, 1993, The Journal of pharmacology and experimental therapeutics.

Characterization of mono- and diaminopyrimidine derivatives as novel, nonpeptide gonadotropin releasing hormone (GnRH) receptor antagonists.

Mark B. Anderson, G. Paderes, D. Luthin, 2002, Bioorganic & medicinal chemistry letters.

Synthesis and biological activity of oxo-7H-benzo[e]perimidine-4-carboxylic acid derivatives as potent, nonpeptide corticotropin releasing factor (CRF) receptor antagonists.

D. Luthin, D. Dhanoa, D. Bhumralkar, 1999, Bioorganic & medicinal chemistry letters.

Effect of Testosterone Suppression on the Pharmacokinetics of a Potent GnRH Receptor Antagonist

Mark B. Anderson, D. Luthin, K. Anderes, 2002, Pharmaceutical Research.

Binding of agonists and antagonists to β-adrenoceptors in rat vas deferens: relationship to functional response

P. Abel, K. Minneman, J. May, 1985, Naunyn-Schmiedeberg's Archives of Pharmacology.

The discovery of novel small molecule non-peptide gonadotropin releasing hormone (GnRH) receptor antagonists.

Mark B. Anderson, G. Paderes, D. Luthin, 2002, Bioorganic & medicinal chemistry letters.

Characterization of 8-(N-methylisopropyl)amino-N6-(5'-endohydroxy- endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors.

R. Wysocki, J. Linden, J. May, 1996, The Journal of pharmacology and experimental therapeutics.